202 related articles for article (PubMed ID: 37593733)
1. Intra-cervical lymphatic immunotherapy for dust mite-induced allergic rhinoconjunctivitis in children: a 3-year prospective randomized controlled trial.
Wang Q; Wang K; Qin Y; Huang W; Li Y; Yu Q; Xiong Y; Guo Y; Zheng R; Tang J
Front Immunol; 2023; 14():1144813. PubMed ID: 37593733
[TBL] [Abstract][Full Text] [Related]
2. The long-term efficacy of intra-cervical lymphatic immunotherapy on adults with allergic rhinitis: A randomized controlled study.
Qin Y; Huang W; Zheng R; Wang Q; Yu Q; Li Y; Wang K; Tang J
Clin Transl Allergy; 2024 Feb; 14(2):e12341. PubMed ID: 38343066
[TBL] [Abstract][Full Text] [Related]
3. [A randomized controlled study on the long-term efficacy of intra-cervical lymphatic immunotherapy for adult allergic rhinitis].
Wang K; Qin Y; Wang QX; Huang WJ; Yu QQ; Li Y; Xiong Y; Guo YW; Tang J
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Sep; 58(9):871-877. PubMed ID: 37675525
[No Abstract] [Full Text] [Related]
4. [Efficacy comparison and safety analysis of subcutaneous specific immunotherapy with standardized house dust mite allergen in patients with single and multiple allergic rhinitis].
Huang HH; Xu C; Liu L; Chai RN
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jun; 56(6):774-783. PubMed ID: 35785859
[No Abstract] [Full Text] [Related]
5. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Subcutaneous Immunotherapy in Monosensitized and Polysensitized Children With Allergic Rhinitis.
Yuan X; Xie S; Zhang H; Zhang J; Fan R; Jiang W; Xie Z
Otolaryngol Head Neck Surg; 2024 Mar; 170(3):919-927. PubMed ID: 38104318
[TBL] [Abstract][Full Text] [Related]
8. [The efficacy and safety of standardized dust mite allergen subcutaneous immunotherapy in children with allergic rhinitis during treatment].
Yuan X; Xie SB; Zhang H; Zhang JY; Wang FJ; Liu YZ; Meng L; Zhong W; Jiang WH; Xie ZH
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2023 Sep; 58(9):878-884. PubMed ID: 37675526
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.
Zhang J; Yang X; Chen G; Hu J; He Y; Ma J; Ma Z; Chen H; Huang Y; Wu Q; Liu Y; Yu L; Zhang H; Lai H; Zhang J; Zhai J; Huang M; Zou Z; Tao A
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):346-354.e1. PubMed ID: 37913839
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of subcutaneous house dust mite immunotherapy in patients with moderate to severe allergic rhinitis.
Valero A; Ibáñez-Echevarría E; Vidal C; Raducan I; Castelló Carrascosa JV; Sánchez-López J
Immunotherapy; 2022 Jun; 14(9):683-694. PubMed ID: 35465692
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
12. One-year evaluation of clinical and immunological efficacy and safety of sublingual versus subcutaneous allergen immunotherapy in allergic conjunctivitis.
Sayed KM; Kamel AG; Ali AH
Graefes Arch Clin Exp Ophthalmol; 2019 Sep; 257(9):1989-1996. PubMed ID: 31209565
[TBL] [Abstract][Full Text] [Related]
13. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients.
Pfaar O; Nell MJ; Boot JD; Versteeg SA; van Ree R; Roger A; Riechelmann H; Sperl A; Oude Elberink JN; Diamant Z; Bachert C
Allergy; 2016 Jul; 71(7):967-76. PubMed ID: 26864207
[TBL] [Abstract][Full Text] [Related]
14. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
15. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
16. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of cervical intralymphatic immunotherapy for house dust mite allergic rhinitis: A pilot study.
Wang K; Zheng R; Chen Y; Yu Q; Zhong H; Xiao P; Wang Y; Tang J
Am J Otolaryngol; 2019; 40(6):102280. PubMed ID: 31519431
[TBL] [Abstract][Full Text] [Related]
18. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
19. [Long-term efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients].
Lou HF; Huang YR; Wang CS; Wang XD; Zhao Y; Cao FF; Zhang L
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Nov; 32(21):1627-1631. PubMed ID: 30400685
[No Abstract] [Full Text] [Related]
20. Suppression function against environmental dust exposure after Dermatophagoides pteronyssinus immunotherapy is associated with production of specific and cross-reactive immunoglobulin G4.
Feng M; Luo T; Xian M; Shi X; Qin R; Zeng X; Su Q; Li J
Clin Exp Allergy; 2022 Jul; 52(7):878-887. PubMed ID: 34962673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
